# Randomized Autologous heMatopoietic Stem Cell Transplantation Versus Alemtuzumab, Cladribine or Ocrelizumab for RRMS (RAM-MS)

> **NCT03477500** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Haukeland University Hospital** · enrollment: 100 (estimated)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** Cyclophosphamide and ATG
- **DRUG:** Alemtuzumab
- **DRUG:** Cladribine Pill
- **DRUG:** Ocrelizumab

## Key facts

- **NCT ID:** NCT03477500
- **Lead sponsor:** Haukeland University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-03-21
- **Primary completion:** 2026-11-21
- **Final completion:** 2028-03-21
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2025-06-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03477500

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03477500, "Randomized Autologous heMatopoietic Stem Cell Transplantation Versus Alemtuzumab, Cladribine or Ocrelizumab for RRMS (RAM-MS)". Retrieved via AI Analytics 2026-09-07 from https://api.ai-analytics.org/clinical/NCT03477500. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*